BIO

For research use only. Not for use in humans.

目录号:S7198 别名: GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052

BIO Chemical Structure

CAS No. 667463-62-9

BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052)是一种特异性的GSK-3抑制剂,无细胞试验中作用于GSK-3α/β的IC50为5 nM,比作用于CDK5选择性高16倍以上,也是一种泛JAK抑制剂,对 Tyk2 的IC50值为30 nM。BIO 可在人类黑色素瘤细胞中诱导凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1286.64 现货
RMB 1206.72 现货
RMB 4671.57 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的BIO发表文献19篇:

产品安全说明书

GSK-3抑制剂选择性比较

生物活性

产品描述 BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052)是一种特异性的GSK-3抑制剂,无细胞试验中作用于GSK-3α/β的IC50为5 nM,比作用于CDK5选择性高16倍以上,也是一种泛JAK抑制剂,对 Tyk2 的IC50值为30 nM。BIO 可在人类黑色素瘤细胞中诱导凋亡。
特性 BIO是第一个维持人类和小鼠的胚胎干细胞自我更新的药理剂。
靶点
GSK-3 [1]
(Cell-free assay)
TYK2 [4]
(Cell-free assay)
CDK5/p35 [1]
(Cell-free assay)
CDK2/CyclinA [1]
(Cell-free assay)
CDK1/CyclinB [1]
(Cell-free assay)
5 nM 30 nM 0.08 μM 0.30 μM 0.32 μM
体外研究

BIO (6-bromoindirubin-3'-oxime)是特异性的GSK-3抑制剂,作用于GSK-3α/β,IC50为5 nM,比作用于CDK5选择性高16倍以上。BIO与这些激酶的ATP结合口袋相互作用,降低β-catenin在GSK-3特异性位点磷酸化。[1]BIO作用于人类和小鼠胚胎干细胞,保持未分化表型,并维持多能状态特异性的转录表达因子Oct-3/4, Rex-1 和 Nanog表达。BIO-介导的Wnt信号激活是功能可逆的,撤掉化合物后,导致人类和小鼠胚胎干细胞的正常多元分化程序。[2]BIO促进哺乳动物心肌细胞增殖。[3] BIO也是pan-JAK抑制剂,作用于TYK2, JAK1, JAK2 和 JAK3,IC50值分别为0.03, 1.5, 8.0, 0.5 μM。BIO选择性抑制STAT3磷酸化,且诱导人类黑色素瘤细胞凋亡。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEI-OC1 NUPkRWtjTnWwY4Tpc44h[XO|YYm= M3;lNHBzd3SnY4Tpc44h[WejaX7zeEBkcXOybHH0bY4ucW6mdXPl[EBk\WyuIHTlZZRpKGmwIH7lc45ifGGuIH3veZNmKEiHST3PR|Eh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPhd5Bie2VvMz:3JIFkfGm4aYT5MEBGSzVyIE2gNE4yQTJizszNMi=> MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7MUmxOUc,OzByOUG5NVU9N2F-
SH-SY5Y M1ztXGZ2dmO2aX;uJIF{e2G7 M3HOVGlvcGmkaYTpc44hd2ZiR2PLN{1u\WSrYYTl[EBj\XSjLXPhd4VqdiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hW0hvU2m1XUBk\WyuczDpckBxemW|ZX7j[UBw\iCPR{GzNkBjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYOsJGlEPTBiPTCwMlI6KM7:TT6= NES1fJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEixOlEyOCd-MUi4NVYyOTB:L3G+
K562 NYTTNFZFSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MkPjO|IhcHK| Mk\RRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLkOg{txONg>? NXXoNYZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3PFMyPDlpPkG5O|g{OTR7PD;hQi=>
IMR90 NGrmOlNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NXr1e4tHPzJiaILz MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEmPUkmwJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLkmg{txONg>? NFnDXXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe4N|E1QSd-MUm3PFMyPDl:L3G+
HCT116 MljyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NWLseINQPzJiaILz M2\NbmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTC1MlIh|ryPLh?= M1HDTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{izNVQ6Lz5zOUe4N|E1QTxxYU6=
HepG2 NVHOelhyS3m2b4TvfIlkcXS7IHHzd4F6 Mn3ONlQhcHK| MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEK0JIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IEWuN{DPxE1w MkPaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEO0PVIoRjJ6N{SzOFkzRC:jPh?=
HL60 NWPhZnVXSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHfwNGI2KGSjeYO= MnrFRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHHmeIVzKDViZHH5d{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3LkSg{txONg>? M2fKZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{izNVQ6Lz5zOUe4N|E1QTxxYU6=
HuH7 M2X4UGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MkDqO|IhcHK| M1TpTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSIXIO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iNj6yJO69VS5? NFHNZ4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe4N|E1QSd-MUm3PFMyPDl:L3G+
SH-SY5Y M2DQOmN6fG:2b4jpZ4l1gSCjc4PhfS=> M1\DbFQ5KGi{cx?= MWLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFNicnXkeYN1cW:wIHHzd4F6NCCLQ{WwJF0hQSEQvF2u M1fT[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OEG2NVExLz5zOEixOlEyODxxYU6=
SH-SY5Y NYfNcnlCTnWwY4Tpc44h[XO|YYm= M13mc|Q5KGi{cx?= NEDRZmdUfXK4aY\hcEBw\iCqdX3hckBUUC2VWUXZJINmdGy|IHHmeIVzKDR6IHjyd{BjgSCPVGOgdoVlfWO2aX;uJIF{e2G7LDDJR|UxKD1iOT61JO69VS5? NIPxXVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNki1OFA3QSd-MU[4OVQxPjl:L3G+
SH-SY5Y M1GwUmZ2dmO2aX;uJIF{e2G7 MmDHSIVifGhib3[gbJVu[W5iU1itV3k2YSClZXzsd{BqdiCjYoPlcoNmKG:oIEKwJJVOKFFvVlStU3BpKGK7IF3UV{Bz\WS3Y4Tpc44h[XO|YYmsJGlEPTBiPTCxNEDPxE1w MnfYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ6NUSwOlkoRjF4OEW0NFY6RC:jPh?=
SH-SY5Y NGDHWmJHfW6ldHnvckBie3OjeR?= Mn;1SIVifGhib3[gbJVu[W5iU1itV3k2YSClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEB2VSCTLW\EMW9RcCCkeTDNWHMhemWmdXP0bY9vKGG|c3H5MEBKSzVyIE2gNVMh|ryPLh?= M2jib|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4OEW0NFY6Lz5zNki1OFA3QTxxYU6=
SH-SY5Y NFjufHBHfW6ldHnvckBie3OjeR?= M3fZU|I1KGi{cx?= Ml\1V5Vzfmm4YXygc4YhcHWvYX6gV2guW1l3WTDj[YxteyCjZoTldkAzPCCqcoOgZpkhVVSVIILl[JVkfGmxbjDhd5NigSxiSVO1NEA:KDF6IN88UU4> NVrCWZJERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[4OVQxPjlpPkG2PFU1ODZ7PD;hQi=>
IMR32 MknGR5l1d3SxeHnjbZR6KGG|c3H5 M2G3e|Q5KGi{cx?= M4r3d2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGlOWjN{IHPlcIx{KGG|c3Xzd4VlKGG|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZk> NIn5ZoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUiwNlk1Pyd-MkG4NFI6PDd:L3G+
SK-N-SH NHvKSXNEgXSxdH;4bYNqfHliYYPzZZk> NV7GUYNGPDhiaILz NF;yNVBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUy2QLWPIJINmdGy|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[Xl? MnfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF6MEK5OFcoRjJzOECyPVQ4RC:jPh?=
NB39 NHTFRmVEgXSxdH;4bYNqfHliYYPzZZk> NFHqSms1QCCqcoO= MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDORlM6KGOnbHzzJIF{e2W|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYm= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOThyMkm0O{c,OjF6MEK5OFc9N2F-
A673 NELMS4lyUFSVIHHzd4F6 M{\0bZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy| NGLid4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY M4GyTpFJXFNiYYPzZZk> MlrSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NWjodnFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2 NETqbXVyUFSVIHHzd4F6 MlHIdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= NIj1S2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 M{HvbJFJXFNiYYPzZZk> MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD M17EV5FJXFNiYYPzZZk> MV3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM> M{XLV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH M4rDWpFJXFNiYYPzZZk> MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= MlfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 NUHZWo5VeUiWUzDhd5NigQ>? MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN? M3e3R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MofNdWhVWyCjc4PhfS=> MoTKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NXHQfJBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NV\LS252eUiWUzDhd5NigQ>? M4HuZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 MVzxTHRUKGG|c3H5 MnPrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= M{TL[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41 MV\xTHRUKGG|c3H5 NXnSWG5QeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoOFEh[2WubIO= NGniS4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 M2KySJFJXFNiYYPzZZk> NU\l[lBKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoN|Ah[2WubIO= MmPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 NUPqOVN{eUiWUzDhd5NigQ>? MkX2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= NG\2fGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC MoPjdWhVWyCjc4PhfS=> NV7TXpk{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> M1\OOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 NFjqWpFyUFSVIHHzd4F6 MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?= NUniT2E2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MWLxTHRUKGG|c3H5 MkTndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy| MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 NHvUdIxyUFSVIHHzd4F6 MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? M3e5SlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A549 MYLGeY5kfGmxbjDhd5NigQ>? NVnTcGxkOTBidV2= NVrBSm9TOTVibXnudy=> NEjNUmlKdmirYnn0bY9vKG:oIHj1cYFvKG2SR1XTNUBnem:vIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgVGdGOiCjdDCxNEB2VSCjZoTldkAyPSCvaX7zJIJ6KEiSTFO= NYjpXlFCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PVczPDRpPkK0Olk4OjR2PD;hQi=>
HEK293 MUHGeY5kfGmxbjDhd5NigQ>? M4rPPVAvPSC2bzCxJJVO NWrIbWpvUW6qaXLpeIlwdiCxZjDoeY1idiCJU1uzJIFkfGm4aYT5JIlvKEiHS{K5N{Bk\WyuczDjc451[WmwaX7nJJRp\SCZboSvZoV1[S2lYYTlcolvKGGldHn2ZZRm\CC{ZYDvdpRmeiCyU4Xw[ZJVV1CITFHTTEApW1SIMkmzJINmdGy|KTDheEAxNjVidH:gNUB2VSCkeTDXcpQhemWyb4L0[ZIh\2WwZTDhd5NigQ>? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ7N{K0OEc,OjR4OUeyOFQ9N2F-
sf9 Ml7oSpVv[3Srb36gZZN{[Xl? M2nTW|EhfU1? M4r3O2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzRiKGO0JJRwKEV|MEOgdoV{cWS3ZYOpM2N6[2yrbjDENUApWTRidH:gTVI6PSC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJJNnQSClZXzsd{BifCBzIIXNJJV{cW6pIGLCMWNVTiCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 MXnGeY5kfGmxbjDhd5NigQ>? MojqNUB2VQ>? Mn70TY5pcWKrdHnvckBw\iCqdX3hckBPNXSncn3pcoFtKEeVVD;IbZM3NXSjZ3fl[EBIW0t|YnX0ZUApVTFidH:gWFQzOCC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoOTDj[YxteyCjdDCxJJVOKHW|aX7nJHJDTVJvSWLTeIll\SCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? NWfP[|l6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1OVc1OzBpPkK4OVU4PDNyPD;hQi=>
sf9 NXHJUIxuTnWwY4Tpc44h[XO|YYm= M1X6WFEhfU1? MmPiTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCQLYTldo1qdmGuIFfTWE11[WepZXSgR2RMOiBqTUGgeI8hVDJ7ODDy[ZNq\HWnczmvR5lkdGmwIFGyJEhOOSC2bzDMOFMzKHKnc3nkeYV{MSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z7IHPlcIx{KGG2IEGgeW0hfXOrbnegTIl{fG:wZTDINUBieyC|dXLzeJJifGViYomg[oltfGW{IHLpcoRqdmdiYYPzZZk> MmjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
sf9 NFv0RZFHfW6ldHnvckBie3OjeR?= MWmxJJVO M1rvUWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDHV3QufGGpZ3XkJGNFUzViKF2xJJRwKFB{OUKgdoV{cWS3ZYOpM5A{PU6FSzCoUVEhfG9iUkOwO{Bz\XOrZIXld{kh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJJNnQSClZXzsd{BifCBzIIXNJJV{cW6pIGLCMWNVTiCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 MlnuSpVv[3Srb36gZZN{[Xl? NHLLNoEyKHWP M4TicWlvcGmkaYTpc44hd2ZiaIXtZY4hVi22ZYLtbY5idCCJU2SvTIl{Pi22YXfn[YQhSXW{b4LhJGIhMEF{IITvJGE{PDRicnXzbYR2\XNrIHX4dJJme3OnZDDpckB{\jliY3XscJMh[XRiMTD1UUB2e2mwZzD0[ZRz[SiOUmLMV2xIMSCjczDzeYJ{fHKjdHWgZpkh\mmudHXyJIJqdmSrbnegZZN{[Xl? MkLOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
sf9 M4rVO2Z2dmO2aX;uJIF{e2G7 NH;NU4cyKHWP MYfJcohq[mm2aX;uJI9nKGi3bXHuJG4ufGW{bXnuZYwhT1OWL1jpd|YufGGpZ3XkJGZITlJzIDjHOFAxKHSxIGK4NlAhemW|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EB{\jliY3XscJMh[XRiMTD1UUB2e2mwZzDQc4x6MEeudTzUfZIqPDpzIHHzJJN2[nO2cnH0[UBjgSCoaXz0[ZIh[mmwZHnu[{Bie3OjeR?= Mn;vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
sf9 NHTaPVVHfW6ldHnvckBie3OjeR?= MWqxJJVO MVHJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKE5vdHXycYlv[WxiR2PUM2hqezZvdHHn[4VlKEOGS{GgLG0yKHSxIF2yPVchemW|aXT1[ZMqN0O7Y3zpckBDOSBqTUGgeI8hXjR|MzDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKHOoOTDj[YxteyCjdDCxJJVOKHW|aX7nJHJDNUOWRjDhd{B{fWK|dILheIUh[nliZnnseIVzKGKrbnTpcoch[XO|YYm= NFLxVZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
sf9 MkTESpVv[3Srb36gZZN{[Xl? NYXuTVJzOSC3TR?= NFHhTppKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygS3NVNXSjZ3fl[EBETEt{IDjNNUB1dyCOMkm4JJJme2mmdXXzLU9EgWOuaX6gSVEhME1zIITvJGE{QTVicnXzbYR2\XNrIHX4dJJme3OnZDDpckB{\jliY3XscJMh[XRiMTD1UUB2e2mwZzDSRk1EXEZiYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7 MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV3N{SzNEc,Ojh3NUe0N|A9N2F-
sf9 NFztWllHfW6ldHnvckBie3OjeR?= NXu5PVhHOSC3TR?= NW\wdI1sUW6qaXLpeIlwdiCxZjDoeY1idiCQLYTldo1qdmGuIFfTWE9JcXN4LYTh[4dm\CCDdYLvdoEhSSBqTUGgeI8hWzRyMzDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIIPmPUBk\WyuczDheEAyKHWPIIXzbY5oKHSndILhLGxTWkyVTFepJIF{KHO3YoP0doF1\SCkeTDmbYx1\XJiYnnu[Ilv\yCjc4PhfS=> Mlm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3NUe0N|AoRjJ6NUW3OFMxRC:jPh?=
sf9 M4rjN2Z2dmO2aX;uJIF{e2G7 Mlq3NUB2VQ>? MmHGTY5pcWKrdHnvckBw\iCqdX3hckBPNXSncn3pcoFtKEeVVD30ZYdo\WRiQYXyc5JiKEJiKF2xJJRwKFN{NzDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKHOoOTDj[YxteyCjdDCxJJVOKHW|aX7nJGNFSzJ3Qz3k[ZJqfmWmIIDldJRq\GViYYOgd5Vje3S{YYTlJIJ6KG[rbITldkBjcW6maX7nJIF{e2G7 NF;2SXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O|Q{OCd-Mki1OVc1OzB:L3G+
HT22 NXTtSYhYTnWwY4Tpc44h[XO|YYm= MoPHNVAhfU1? NUPQfHZXOjRiaILz MWPJcohq[mm2aX;uJI9nKEeVS{OtcYVlcWG2ZXSgZoV1[SClYYPlbY4heGixc4Doc5J6dGG2aX;uJIlvKG2xdYPlJGhVOjJiY3XscJMh[XRiMUCgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kBOTzF|Mh?= NYPNfFVJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5PVg1PDNpPkKyPVk5PDR|PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p21 / p27 ; 

PubMed: 27510556     


In BIO treatment of cardiac fibroblasts for 1 day, the protein levels of phosphorylated Akt, p21, and p27 were assessed.

p-β-catenin / β-catenin ; 

PubMed: 27211495     


ERKi and GSK3i differently regulate PI3K/Akt and β-catenin pathways. U0126 increased while BIO decreased Akt phosphorylation after 24 hours of treatment. BIO prevented β-catenin phosphorylation leading to intact β-catenin accumulation, while U0126 only had a marginal effect.

FoxO3a / FoxO1 / p-FoxO3a / p-FoxO1 ; 

PubMed: 27211495     


U0126 markedly increased the phosphorylation of Akt downstream targets FOXO1 and FOXO3a, while BIO decreased it.

27510556 27211495
Immunofluorescence
pAKT / p21 / p27 ; 

PubMed: 27510556     


Protein expressions of pAkt, p21 and p27 were determined by immunofluorescence staining in cardiac fibroblasts treated with BIO for 1 day. *p < 0.05, t-test. Scale bar = 100 μm.

TNF-α; 

PubMed: 24286133     


Detection of TNF-α protein expression by immunofluorescence microscopy. Nucleus pulposus cells were cultured with or without 1.0 μM BIO for 24 h, fixed, and stained with an antibody against c-fos. Left: cells stained with an antibody to TNF-α; middle: cells stained with 4′,6-diamidino-2-phenylindole (DAPI), to identify healthy nuclei; right: cells stained with an antibody to TNF-α and with DAPI. Scale bar, 50 μm (original magnification, 20×).

E-cadherin / Nanog ; 

PubMed: 25538040     


hESCs were treated with either vehicle (Veh) or BIO for 6 hours. Twenty-four hours after removal of BIO, hESCs exhibit thick and compact colonies that express higher levels of E‐cadherin (E‐cad) and Nanog.

Oct3/4; 

PubMed: 25538040     


hESCs were treated with either vehicle (Veh) or BIO for 6 hours. Twenty‐four hours after removal of BIO, hESCs exhibit thick and compact colonies that express higher levels of E‐cadherin (E‐cad) and Oct3/4. In contrast, long-term BIO treatment leads to opposing results. Scale bar = 20 µm.

27510556 24286133 25538040
Growth inhibition assay
Cell proliferation ; 

PubMed: 27510556     


The increase in cardiomyocyte proliferation after treatment with BIO for 4 days was also confirmed by MTT assay.

27510556
体内研究 BIO处理小鼠移植瘤模型,抑制黑色素瘤生长。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

激酶实验:

在Buffer A 或 C中在30°C下进行激酶活性检测,ATP 终浓度为15 μM。减去空白值,活性计算为在10分钟温育期间渗透的皮摩尔磷酸盐。使用适当的DMSO稀释液作为对照。在一些情况下通过SDS-PAGE后放射自显影测评底物的磷酸化。通过亲和层析法,从猪脑中纯化GSK-3α/β。检测中, 在15 μM[γ-32P] ATP (3,000 Ci/mmol;1 mCi/ml) 存在时,含5 μl 40 μM GS-1肽, 一种特异性GSK-3底物(YRRAAVPPSPSLSRHSSPHQSpEDEEE)的1 mg BSA/ml 10 mM DTT在buffer A中按1/100稀释,终体积为30 μl。在30°C下温育30分钟后,25 μl上清液等分试样点样到2.5×3 cm Whatman P81磷酸纤维素纸片上,20秒后,过滤器在10 ml磷酸/升水的溶液中洗涤5次(每次至少5分钟)。在1 ml ACS闪烁液存在时,对湿的过滤器进行计数。
细胞实验:[1]
- 合并
  • Cell lines: COS1, Hepa 或 SH-SY5Y 细胞
  • Concentrations: ~10 μM
  • Incubation Time: 12 或 24 小时
  • Method: COS1, Hepa (野生型, CEM/LM AhR 缺陷和 ELB1 ARNT 缺陷), 或 SH-SY5Y细胞在6 cm 培养皿中生长,培养基为含10%胎牛血清的DMEM培养基。当细胞密度达到〜70%汇合上,IO (5 μM), BIO (5 或 10 μM), MeBIO (5或50 μM), LiCl (20或40 mM), 或模拟液 (DMSO, 终浓度为0.5% )加入到培养基中。12 小时(SH-SY5Y) 或24小时后 使用裂解缓冲液(1% SDS, 1 mM原钒酸钠, 10 mM Tris [pH 7.4])裂解仍在实验板上的细胞。裂解液通过26G针头数次,在10,000×g下离心5分钟,调整到相等蛋白质浓度。上样约8 μg每种样品,用于免疫印迹分析。增强的化学发光是用于检测。使用如下一抗:小鼠anti-β-catenin CT(识别总β-catenin), 小鼠anti-phospho-β-catenin(识别去磷酸化的β-catenin), 小鼠anti-GSK-3β, 小鼠anti-GSK-3 phosphoTyr216, 兔anti-AhR(芳香烃受体), 及兔anti-Actin。
    (Only for Reference)
动物实验:[4]
- 合并
  • Animal Models: 小鼠
  • Dosages: 50 mg/kg
  • Administration: 口服饲喂
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 71 mg/mL (199.34 mM)
Water Insoluble
Ethanol '6 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+50%ddH2O
3 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 356.17
化学式

C16H10BrN3O2

CAS号 667463-62-9
储存条件 粉状
溶于溶剂
别名 GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04263519 Not yet recruiting Drug: Tacrolimus Alzheimer Disease|Mild Cognitive Impairment Massachusetts General Hospital December 1 2021 Phase 2
NCT04889183 Not yet recruiting Drug: Semaglutide|Drug: Placebo Obesity|Albuminuria University Medical Center Groningen|Novo Nordisk A/S September 2021 Phase 3

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

GSK-3 Signaling Pathway Map

相关GSK-3产品

Tags: 购买BIO | BIO供应商 | 采购BIO | BIO价格 | BIO生产 | 订购BIO | BIO代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID